AI Article Synopsis
- Leber's congenital amaurosis is a hereditary retinal disorder that severely impacts vision in children, leading to narrowing visual fields and eventual loss of central vision, primarily linked to mutations in the RPE65 gene.
- This study focuses on two Hungarian patients who received the innovative gene therapy voretigene neparvovec for treating their RPE65-related vision issues.
- Results showed both patients experienced improved visual acuity and less visual field narrowing, significantly enhancing their quality of life, aligning with previous clinical trial outcomes.
Article Abstract
Introduction: Leber's congenital amaurosis is a genetically determined disease belonging to the group of hereditary retinal dystrophies that leads to significant visual impairment in childhood. The disease initially causes a concentric narrowing of the visual field and, with time, loss of central vision. The RPE65 gene mutation-related retinal dystrophy is the first ophthalmic disease for which gene therapy is available using voretigene neparvovec (Luxturna®, Novartis Pharmaceuticals AG, Basel, Switzerland).
Objective: To present the treatment outcomes of Hungarian patients who were the first to receive voretigene neparvovec gene therapy for the RPE65 biallelic gene mutation.
Method: Two patients with RPE65 biallelic gene mutations confirmed by genetic testing received voretigene neparvovec gene therapy in one eye each. Before treatment and during the follow-up period, we assessed the best corrected visual acuity, the central retinal thickness, the degree of visual field defects and performed electrophysiological studies.
Results: Both the best corrected visual acuity (+3 letters in the older sibling and +10 letters in the younger sibling) and the degree of visual field narrowing improved in both patients. The change in visual function resulted in a significant improvement in the quality of life of our patients.
Conclusion: Postoperative outcomes of our patients correlate with the results of clinical trials. Orv Hetil. 2022; 163(48): 1923-1931.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1556/650.2022.32636 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insights into the effects of subretinal voretigene neparvovec-rzyl in RPE65-associated Leber congenital amaurosis: an 18-Month report.
Can J Ophthalmol
January 2025
Department of Ophthalmology and Vision Sciences, the Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; Program in Genetics & Genome Biology, SickKids Research Institute, Toronto, ON, Canada. Electronic address:
Objective: Assess safety and effectiveness of subretinal gene replacement therapy at 18 months post treatment.
Design: Retrospective, longitudinal study conducted at the Hospital for Sick Children in Toronto, Canada.
Participants: Patients with bi-allelic RPE65 variants, early onset retinal degeneration, and residual viable retina who underwent voretigene neparvovec r-zyl gene replacement therapy.
"Blindness" is not a contraindication for voretigene neparvovec-rzyl treatment: a review of 9 cases.
Can J Ophthalmol
January 2025
Department of Ophthalmology and Vision Sciences, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. Electronic address:
Objective: Biallelic RPE65 pathogenic variants may cause Leber congenital amaurosis (LCA). Voretigene neparvovec-rzyl (VN, Luxturna) is the only approved subretinal gene therapy that demonstrated benefit and safety. The eligibility criteria are vague and variable between centres.
View Article and Find Full Text PDFDeep Learning-Based SD-OCT Layer Segmentation Quantifies Outer Retina Changes in Patients With Biallelic RPE65 Mutations Undergoing Gene Therapy.
Invest Ophthalmol Vis Sci
January 2025
Institute for Applied Mathematics, University of Bonn, Bonn, Germany.
Purpose: To quantify outer retina structural changes and define novel biomarkers of inherited retinal degeneration associated with biallelic mutations in RPE65 (RPE65-IRD) in patients before and after subretinal gene augmentation therapy with voretigene neparvovec (Luxturna).
Methods: Application of advanced deep learning for automated retinal layer segmentation, specifically tailored for RPE65-IRD. Quantification of five novel biomarkers for the ellipsoid zone (EZ): thickness, granularity, reflectivity, and intensity.
Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions.
Yale J Biol Med
December 2024
Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, USA.
Ocular gene therapy has rapidly advanced from proof-of-concept studies to clinical trials by exploiting the unique advantages of the eye, including its easy accessibility, relative immune privilege, and the ability to use the contralateral eye as a control. An important step forward was achieved with the Food and Drug Administration (FDA) approval of voretigene neparvovec (Luxturna) for the treatment of biallelic RPE65-mutation-associated retinal dystrophies in 2017. Gene therapy is a promising field aimed at treating various inherited and acquired eye diseases.
View Article and Find Full Text PDF12-month outcomes after voretigene neparvovec gene therapy in paediatric patients with -mediated inherited retinal dystrophy.
Br J Ophthalmol
November 2024
Ophthalmology Department, Necker-Enfants Malades University Hospital, AP-HP, Paris Cité University, 149 Rue de Sèvres, 75015 Paris, France, Paris, France.
Aims: To report main outcomes and complications following voretigene neparvovec (Luxturna) treatment in paediatric patients.
Methods: Records of patients under the age of 17 treated by subretinal administration of voretigene neparvovec for confirmed biallelic -mediated inherited retinal dystrophy were retrospectively reviewed. Best-corrected visual acuity (BCVA) and data from spectral-domain optical coherence tomography, ultra-wide-field fundus imaging and Goldmann visual field (VF) were analysed at 12 months follow-up.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!